Abstract 5593
Background
MicroRNA-21 (miR-21) is a small non-coding RNA that inhibits target genes expression thus affects tumorigenesis. Ki-67 is a nucleolar protein antigen in proliferating cells.Ki-67 expression is highly correlated with the proliferation rate. Immunohistochemical assay (IHC) of Ki67 antigen in paraffin section (Ki67 proliferative index) represents the active growth fraction of the tumor. We aim to evaluate the diagnostic and prognostic value of miR-21 and ki-67 as a potential biomarker of non- Hodgkin`s lymphoma (NHL).
Methods
We prospectively enrolled NHL patients (2017-2018). Serum MiR-21 and tissue Ki-67 were assessed with RT- PCR and IHC of lymph node biopsy respectively. The primary outcomes were to identify overall survival (OS), and progression free survival (PFS), while the secondary outcomes were to identify the associations between different variables and miR-21 and Ki-67. Spearman’s correlation was used and expressed as correlation coefficient (r). Kaplan-Meier survival curves were used and compared using Log-rank. Cox regression was used to identify the independent predictors of survival.
Results
80 patients were recruited with median age of 56.5 years (Inter-quartile range: 47- 64.8), 50% were males. DLBCL represented 80%. 53/73 known responses (72.6%) were responders (partial or complete response). Higher miR-21 was noticed among patients with B symptoms (r = 0.304, P = 0.006), higher extra-nodal number (r = 0.341, P = 0.002), stage IV (r = 0.221, P = 0.048), LDH (r = 0.287, P = 0.010), BMB infiltration (r = 0.230, P = 0.040), international prognostic index (IPI) (r = 0.511, P < 0.001). Lower miR-21 was noticed among females (r= -0.258, P = 0.021). Higher Ki-67 was noticed among old age (r = 0.330, P = 0.005), diffuse large B cell lymphoma (DLBCL) vs other diagnoses (r = 0.315, P = 0.008). On multivariable analyses, Ki-67 was associated with worse OS (HR 1.033 (95%CI 1.002-1.066), P = 0.038) and PFS (HR 1.032 (95%CI 1.010-1.054), P = 0.004).
Conclusions
Plasma miRNA-21 may be employed as valuable non-invasive diagnostic marker in NHL. High miR-21 was noticed among high LDH, advanced stages and high IPI patients. Ki-67 is a significant predictors of overall survival, and progression free survival in NHL. Higher Ki-67 was noticed among elderly and DLBCL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5328 - Non-Hodgkin lymphoma in HIV-positive patients treated with antiretroviral therapy and chemotherapy: a single institution retrospective study
Presenter: Davide Dalu
Session: Poster Discussion – Haematological malignancies
Resources:
Abstract
5925 - Obstetric and maternal outcome of 134 patients with Hodgkin lymphoma diagnosed during pregnancy: results from the INCIP registry
Presenter: Frederic Amant
Session: Poster Discussion – Haematological malignancies
Resources:
Abstract
5144 - Mutational profiling through exome sequencing along with MYD88 L265P analysis could facilitate the diagnosis of Vitreoretinal lymphoma
Presenter: Hyeonah Lee
Session: Poster Discussion – Haematological malignancies
Resources:
Abstract
2415 - Treatment outcomes and pattern of failure in primary gastric diffuse large B cell lymphoma with complete remission following R-CHOP chemotherapy
Presenter: Hye Jin Kang
Session: Poster Discussion – Haematological malignancies
Resources:
Abstract
4969 - Treatment outcome for gastric mucosa-associated lymphoid tissue lymphoma with Helicobacter Pylori negative
Presenter: Sung-Nam Lim
Session: Poster Discussion – Haematological malignancies
Resources:
Abstract
Poster Discussion – Haematological malignancies - Invited Discussant 1068PD and 1069PD
Presenter: Maria Gomes da Silva
Session: Poster Discussion – Haematological malignancies
Resources:
Slides
Webcast
Invited Discussant 1070PD
Presenter: Markus Manz
Session: Poster Discussion – Haematological malignancies
Resources:
Slides
Webcast